This June witnessed an unprecedented surge in innovative drug companies listing on the Hong Kong Stock Exchange, with nearly 15 firms submitting IPO applications, a new benchmark in the industry. Simultaneously, CSPC Pharmaceutical Group posed a significant challenge to Ascletis Pharma's GLP-1 US patent, capturing widespread attention within the sector. On the vaccine front, Recovax Biotech inked a collaboration deal with an Indian company for the recombinant nine-valent HPV vaccine. Furthermore, several companies have achieved notable milestones in new drug R&D, securing clinical licenses spanning diverse therapeutic areas including oncology, hepatitis B, and obesity. Hengrui Medicine's JAK1 inhibitor has garnered approval for treating severe alopecia areata in adults, while its savolitinib combination therapy has also been cleared for marketing. Additionally, Meixin Health has filed a prospectus with the Hong Kong Stock Exchange, signaling its intent to list in Hong Kong, underscoring the capital market's enduring interest in the healthcare sector.